Method and system to modify an individual's gut-brain axis to provide neurocognitive protection

A method for modifying an individual's gut-brain axis to provide neurocognitive protection, comprising,

• providing an individual human being with a population of beneficial bacteria selected from the group consisting of at least two bacteria selected from the group consisting of Blautia, Coprococcus, Faecalibacterium prausnitzii;
• Nitrosomonas eutropha, Roseburia intestinalis, Lactobacillus paracasei, and Lactobacillus plantarum;
• administering fiber to the individual to maintain a therapeutically effective amount of the beneficial bacteria in the gut of the individual;
• and
• wherein the bacterial formulation generates an amount of tryptophan metabolites sufficient to act as aryl hydrocarbon receptor (AHR) agonists and thereby reduce inflammation in the individual's gut;
• wherein at least some bacteria in the bacterial formulation have been modified by using a using a clustered regularly interspaced short palindromic repeats (CRISPR) CRISPR associated protein (Cas) system or a CRISPR from Prevotella and Francisella 1 (Cpf1) system to enhance the generation of a tryptophan metabolite, and wherein the beneficial bacteria are encapsulated in a frangible enclosure, increasing the populations of at least two of the following in the individual's gut microbiome:
• Akkermansia muciniphila, Faecalibacterium prausnitzii, Bifidobacterium longum, Roseburia intestinalis, Coprococcus spp. and Veillonella, and inhibiting monoacylglycerolacyltransferase-3 (MGAT3) synthesis in the individual to lower triacylglycerol (TAG) production.

A method for modifying an individual's gut-brain axis to provide neurocognitive protection, comprising,

• providing an individual human being with a population of beneficial bacteria selectedfrom the group consisting of at least two bacteria selected from the group consisting of;
• Akkermansia muciniphila, Faecalibacterium prausnitzii, Bifidobacterium longum, Roseburia intestinalis, Coprococcus spp., Lactobacillus paracasei, Nitrosomonas eutropha, Blautia, Lactobacillus plantarum and Veillonella,
• administering fiber to the individual to maintain a therapeutically effective amount of the beneficial bacteria in the gut of the individual;
• and
• wherein the bacterial formulation generates an amount of tryptophan metabolites sufficient to act as aryl hydrocarbon receptor (AHR) agonists and thereby reduce inflammation in the individual's gut;
• wherein the beneficial bacteria are encapsulated in a frangible enclosure.